The MM cohorts on anti-CD38 or anti-BCMA regimens (G3) also showed a disparate outcome with a low response rate of ~50% with stronger NAb development in half of the patients and lack thereof in the other half. The gene discussed is CD38; the disease is Miyoshi myopathy.